Somatic Mutations Associated with Leukemic Progression of Familial Platelet Disorder with Predisposition to Acute Myeloid Leukemia

Overview

Journal Leukemia

Specialties Hematology
Oncology

Date 2015 Aug 29

PMID 26316320

Citations 43

Authors

I Antony-Debre

N Duployez

M Bucci

S Geffroy

J-B Micol

A Renneville

N Boissel

N Dhedin

D Rea

B Nelken

C Berthon

T Leblanc

M-J Mozziconacci

R Favier

P G Heller

O Abdel-Wahab

H Raslova

V Latger-Cannard

C Preudhomme

Affiliations

Soon will be listed here.

Citing Articles

Disease characteristics and outcomes of acute myeloid leukemia in germline deficiency (Familial Platelet Disorder with associated Myeloid Malignancy).

Ernst M, Versluis J, Valk P, Bierings M, Tamminga R, Hooimeijer L Hemasphere. 2025; 9(1):e70057.

PMID: 39822584 PMC: 11735945. DOI: 10.1002/hem3.70057.

Germ line ERG haploinsufficiency defines a new syndrome with cytopenia and hematological malignancy predisposition.

Zerella J, Homan C, Arts P, Lin X, Spinelli S, Venugopal P Blood. 2024; 144(17):1765-1780.

PMID: 38991192 PMC: 11530364. DOI: 10.1182/blood.2024024607.

Acute myeloid leukemia with rare recurring translocations-an overview of the entities included in the international consensus classification.

Rorvik S, Torkildsen S, Bruserud O, Anderson Tvedt T Ann Hematol. 2024; 103(4):1103-1119.

PMID: 38443661 PMC: 10940453. DOI: 10.1007/s00277-024-05680-5.

Clonal evolution in inherited marrow failure syndromes predicts disease progression.

Schratz K Hematology Am Soc Hematol Educ Program. 2023; 2023(1):125-134.

PMID: 38066914 PMC: 10727088. DOI: 10.1182/hematology.2023000469.

Genomic landscape of patients with germline RUNX1 variants and familial platelet disorder with myeloid malignancy.

Yu K, Deuitch N, Merguerian M, Cunningham L, Davis J, Bresciani E Blood Adv. 2023; 8(2):497-511.

PMID: 38019014 PMC: 10837196. DOI: 10.1182/bloodadvances.2023011165.

References

Yoshimi A, Toya T, Kawazu M, Ueno T, Tsukamoto A, Iizuka H . Recurrent CDC25C mutations drive malignant transformation in FPD/AML. Nat Commun. 2014; 5:4770. DOI: 10.1038/ncomms5770. View

Bluteau D, Gilles L, Hilpert M, Antony-Debre I, James C, Debili N . Down-regulation of the RUNX1-target gene NR4A3 contributes to hematopoiesis deregulation in familial platelet disorder/acute myelogenous leukemia. Blood. 2011; 118(24):6310-20. DOI: 10.1182/blood-2010-12-325555. View

Gaidzik V, Bullinger L, Schlenk R, Zimmermann A, Rock J, Paschka P . RUNX1 mutations in acute myeloid leukemia: results from a comprehensive genetic and clinical analysis from the AML study group. J Clin Oncol. 2011; 29(10):1364-72. DOI: 10.1200/JCO.2010.30.7926. View

Boissel N, Leroy H, Brethon B, Philippe N, De Botton S, Auvrignon A . Incidence and prognostic impact of c-Kit, FLT3, and Ras gene mutations in core binding factor acute myeloid leukemia (CBF-AML). Leukemia. 2006; 20(6):965-70. DOI: 10.1038/sj.leu.2404188. View

Antony-Debre I, Manchev V, Balayn N, Bluteau D, Tomowiak C, Legrand C . Level of RUNX1 activity is critical for leukemic predisposition but not for thrombocytopenia. Blood. 2014; 125(6):930-40. PMC: 4347283. DOI: 10.1182/blood-2014-06-585513. View

Prebet T, Carbuccia N, Raslova H, Favier R, Rey J, Arnoulet C . Concomitant germ-line RUNX1 and acquired ASXL1 mutations in a T-cell acute lymphoblastic leukemia. Eur J Haematol. 2013; 91(3):277-279. DOI: 10.1111/ejh.12147. View

Heller P, Glembotsky A, Gandhi M, Cummings C, Pirola C, Marta R . Low Mpl receptor expression in a pedigree with familial platelet disorder with predisposition to acute myelogenous leukemia and a novel AML1 mutation. Blood. 2005; 105(12):4664-70. DOI: 10.1182/blood-2005-01-0050. View

Pabst T, Eyholzer M, Haefliger S, Schardt J, Mueller B . Somatic CEBPA mutations are a frequent second event in families with germline CEBPA mutations and familial acute myeloid leukemia. J Clin Oncol. 2008; 26(31):5088-93. DOI: 10.1200/JCO.2008.16.5563. View

Liew E, Owen C . Familial myelodysplastic syndromes: a review of the literature. Haematologica. 2011; 96(10):1536-42. PMC: 3186316. DOI: 10.3324/haematol.2011.043422. View

10.

Beri-Dexheimer M, Latger-Cannard V, Philippe C, Bonnet C, Chambon P, Roth V . Clinical phenotype of germline RUNX1 haploinsufficiency: from point mutations to large genomic deletions. Eur J Hum Genet. 2008; 16(8):1014-8. DOI: 10.1038/ejhg.2008.89. View

11.

Meyer S, Levine R . Translational implications of somatic genomics in acute myeloid leukaemia. Lancet Oncol. 2014; 15(9):e382-94. DOI: 10.1016/S1470-2045(14)70008-7. View

12.

Micol J, Duployez N, Boissel N, Petit A, Geffroy S, Nibourel O . Frequent ASXL2 mutations in acute myeloid leukemia patients with t(8;21)/RUNX1-RUNX1T1 chromosomal translocations. Blood. 2014; 124(9):1445-9. PMC: 4148766. DOI: 10.1182/blood-2014-04-571018. View

13.

Preudhomme C, Renneville A, Bourdon V, Philippe N, Roche-Lestienne C, Boissel N . High frequency of RUNX1 biallelic alteration in acute myeloid leukemia secondary to familial platelet disorder. Blood. 2009; 113(22):5583-7. DOI: 10.1182/blood-2008-07-168260. View

14.

Polprasert C, Schulze I, Sekeres M, Makishima H, Przychodzen B, Hosono N . Inherited and Somatic Defects in DDX41 in Myeloid Neoplasms. Cancer Cell. 2015; 27(5):658-70. PMC: 8713504. DOI: 10.1016/j.ccell.2015.03.017. View